Search Results - "Sandler, Howard M"

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options by Sanda, Martin G., Cadeddu, Jeffrey A., Kirkby, Erin, Chen, Ronald C., Crispino, Tony, Fontanarosa, Joann, Freedland, Stephen J., Greene, Kirsten, Klotz, Laurence H., Makarov, Danil V., Nelson, Joel B., Rodrigues, George, Sandler, Howard M., Taplin, Mary Ellen, Treadwell, Jonathan R.

“…This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing…”
Get full text

Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual by Buyyounouski, Mark K., Choyke, Peter L., McKenney, Jesse K., Sartor, Oliver, Sandler, Howard M., Amin, Mahul B., Kattan, Michael W., Lin, Daniel W.

“…Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) Staging Manual has been…”
Get full text

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options by Sanda, Martin G., Cadeddu, Jeffrey A., Kirkby, Erin, Chen, Ronald C., Crispino, Tony, Fontanarosa, Joann, Freedland, Stephen J., Greene, Kirsten, Klotz, Laurence H., Makarov, Danil V., Nelson, Joel B., Rodrigues, George, Sandler, Howard M., Taplin, Mary Ellen, Treadwell, Jonathan R.

“…This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing…”
Get full text

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer by Xie, Wanling, Regan, Meredith M, Buyse, Marc, Halabi, Susan, Kantoff, Philip W, Sartor, Oliver, Soule, Howard, Clarke, Noel W, Collette, Laurence, Dignam, James J, Fizazi, Karim, Paruleker, Wendy R, Sandler, Howard M, Sydes, Matthew R, Tombal, Bertrand, Williams, Scott G, Sweeney, Christopher J

“…Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall…”
Get full text

Preliminary Toxicity Analysis of 3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy on the High-Dose Arm of the Radiation Therapy Oncology Group 0126 Prostate Cancer Trial by Michalski, Jeff M., MD, Yan, Yan, MD, MS, Watkins-Bruner, Deborah, PhD, Bosch, Walter R., DSc, Winter, Kathryn, MS, Galvin, James M., DSc, Bahary, Jean-Paul, MD, Morton, Gerard C., MB, Parliament, Matthew B., MD, Sandler, Howard M., MD

“…Purpose To give a preliminary report of clinical and treatment factors associated with toxicity in men receiving high-dose radiation therapy (RT) on a phase 3…”
Get full text

Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer by Jones, Christopher U, Hunt, Daniel, McGowan, David G, Amin, Mahul B, Chetner, Michael P, Bruner, Deborah W, Leibenhaut, Mark H, Husain, Siraj M, Rotman, Marvin, Souhami, Luis, Sandler, Howard M, Shipley, William U

“…A course of androgen-deprivation therapy before and during radiotherapy prolonged 10-year survival by about 7% among men with intermediate-risk prostate…”
Get full text

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer by HORWITZ, Eric M, BAE, Kyounghwa, SHIPLEY, William U, HANKS, Gerald E, PORTER, Arthur, GRIGNON, David J, BRERETON, Harmar D, VENKATESAN, Varagur, LAWTON, Colleen A, ROSENTHAL, Seth A, SANDIER, Howard M

“…To determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation…”
Get full text

Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement by Freedland, Stephen J, Rumble, R Bryan, Finelli, Antonio, Chen, Ronald C, Slovin, Susan, Stein, Mark N, Mendelson, David S, Wackett, Colin, Sandler, Howard M

“…To endorse the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on adjuvant and salvage radiotherapy after…”
Get full text

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202 by Lawton, Colleen A.F., MD, Lin, Xiaolei, MS, Hanks, Gerald E., MD, Lepor, Herbert, MD, Grignon, David J., MD, Brereton, Harmar D., MD, Bedi, Meena, MD, Rosenthal, Seth A., MD, Zeitzer, Kenneth L., MD, Venkatesan, Varagur M., MD, Horwitz, Eric M., MD, Pisansky, Thomas M., MD, Kim, Harold, MD, Parliament, Matthew B., MD, Rabinovitch, Rachel, MD, Roach, Mack, MD, Kwok, Young, MD, Dignam, James J., PhD, Sandler, Howard M., MD

“…Abstract Purpose Trial*** was a phase III randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with…”
Get full text

Prediction of Erectile Function Following Treatment for Prostate Cancer by Alemozaffar, Mehrdad, Regan, Meredith M, Cooperberg, Matthew R, Wei, John T, Michalski, Jeff M, Sandler, Howard M, Hembroff, Larry, Sadetsky, Natalia, Saigal, Christopher S, Litwin, Mark S, Klein, Eric, Kibel, Adam S, Hamstra, Daniel A, Pisters, Louis L, Kuban, Deborah A, Kaplan, Irving D, Wood, David P, Ciezki, Jay, Dunn, Rodney L, Carroll, Peter R, Sanda, Martin G

“…CONTEXT Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools…”
Get full text

Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials by CHEN, Ronald C, CHANG, Peter, VETTER, Richard J, LUKKA, Himansu, STOKES, William A, SANDA, Martin G, WATKINS-BRUNER, Deborah, REEVE, Bryce B, SANDLER, Howard M

“…The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee convened four working groups to recommend core…”
Get full text

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910 by Pisansky, Thomas M, Hunt, Daniel, Gomella, Leonard G, Amin, Mahul B, Balogh, Alexander G, Chinn, Daniel M, Seider, Michael J, Duclos, Marie, Rosenthal, Seth A, Bauman, Glenn S, Gore, Elizabeth M, Rotman, Marvin Z, Lukka, Himanshu R, Shipley, William U, Dignam, James J, Sandler, Howard M

“…To determine whether prolonged androgen suppression (AS) duration before radiotherapy improves survival and disease control in prostate cancer. One thousand…”
Get full text

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 by EFSTATHIOU, Jason A, BAE, Kyounghwa, SHIPLEY, William U, HANKS, Gerald E, PILEPICH, Miljenko V, SANDIER, Howard M, SMITH, Matthew R

“…Gonadotropin-releasing hormone (GnRH) agonists are associated with greater risk of coronary heart disease and myocardial infarction in men with prostate…”
Get full text

Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06 by EFSTATHIOU, Jason A, BAE, Kyounghwa, SHIPLEY, William U, KAUFMAN, Donald S, HAGAN, Michael P, HENEY, Niall M, SANDLER, Howard M

“…In selected patients with muscle-invasive bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy,…”
Get full text

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer by Lukka, Himanshu R., Pugh, Stephanie L., Bruner, Deborah W., Bahary, Jean-Paul, Lawton, Colleen A.F., Efstathiou, Jason A., Kudchadker, Rajat J., Ponsky, Lee E., Seaward, Samantha A., Dayes, Ian S., Gopaul, Darindra D., Michalski, Jeff M., Delouya, Guila, Kaplan, Irving D., Horwitz, Eric M., Roach, Mack, Pinover, Wayne H., Beyer, David C., Amanie, John O., Sandler, Howard M., Kachnic, Lisa A.

“…There is considerable interest in very short (ultrahypofractionated) radiation therapy regimens to treat prostate cancer based on potential radiobiological…”
Get full text

Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer by Gray, Phillip J., Paly, Jonathan J., Yeap, Beow Y., Sanda, Martin G., Sandler, Howard. M., Michalski, Jeff M., Talcott, James A., Coen, John J., Hamstra, Daniel A., Shipley, William U., Hahn, Stephen M., Zietman, Anthony L., Bekelman, Justin E., Efstathiou, Jason A.

“…BACKGROUND: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment with 3‐dimensional conformal…”
Get full text

Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy by STEPHENSON, Andrew J, SCARDINO, Peter T, FORMAN, Jeffrey D, ZELEFSKY, Michael J, KESTIN, Larry L, ROEHRBORN, Claus G, CATTON, Charles N, DEWEESE, Theodore L, LIAUW, Stanley L, VALICENTI, Richard K, KUBAN, Deborah A, POLLACK, Alan, KATTAN, Michael W, PISANSKY, Thomas M, SLAWIN, Kevin M, KLEIN, Eric A, ANSCHER, Mitchell S, MICHALSKI, Jeff M, SANDLER, Howard M, LIN, Daniel W

“…An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy…”
Get full text

Why Do Parents Become Involved? Research Findings and Implications by Hoover‐Dempsey, Kathleen V., Walker, Joan M. T., Sandler, Howard M., Whetsel, Darlene, Green, Christa L., Wilkins, Andrew S., Closson, Kristen

“…A decade ago, Hoover‐Dempsey and Sandler offered a model of the parental involvement process that focused on understanding why parents become involved in their…”
Get full text

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial by Movsas, Benjamin, Rodgers, Joseph P, Elshaikh, Mohamed A, Martinez, Alvaro A, Morton, Gerard C, Krauss, Daniel J, Yan, Di, Citrin, Deborah E, Hershatter, Bruce W, Michalski, Jeff M, Ellis, Rodney J, Kavadi, Vivek S, Gore, Elizabeth M, Gustafson, Gary S, Schulz, Craig A, Velker, Vikram M, Olson, Adam C, Cury, Fabio L, Papagikos, Michael A, Karrison, Theodore G, Sandler, Howard M, Bruner, Deborah W

“…To report patient-reported outcomes (PROs) of a phase III trial evaluating total androgen suppression (TAS) combined with dose-escalated radiation therapy (RT)…”
Get full text

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233 by Mitin, Timur, MD, George, Asha, MS, Zietman, Anthony L., MD, Heney, Niall M., MD, Kaufman, Donald S., MD, Uzzo, Robert G., MD, Dreicer, Robert, MD, Wallace, H. James, MD, Souhami, Luis, MD, Dobelbower, M. Chris, MD, Sandler, Howard M., MD, Shipley, William U., MD

“…Purpose To investigate the differences in outcomes among patients with muscle-invasive bladder cancer on NRG Oncology Radiation Therapy Oncology Group…”
Get full text